Skip to main content

Table 2 Operative factors and findings (N = 70)a

From: The Carpentier-Edwards Perimount Magna mitral valve bioprosthesis: intermediate-term efficacy and durability

Operative factors  
Indication  
 MR 49 (70 %)
 MS 19 (27 %)
 Endocarditis 10 (14.2 %)
Attempted repair  
 Yes 7 (10 %)
 No 63 (90 %)
Minimally invasive Magna valve implantation  
 Yes 1 (1.4 %)
 No (i.e., full sternotomy) 69 (99 %)
Technique for Magna valve implantation  
 Transseptal approach 49 (70 %)
 Left atriotomy 21 (30 %)
 Subvalvular leaflet preservation 56 (80 %)
Magna valve sizeb (mm) 28 ± 0.3
 25 18 (26 %)
 27 16 (23 %)
 29 19 (27 %)
 31 16 (23 %)
 33 1 (1.4 %)
Findings  
 Rheumatic disease 12 (17 %)
 Myxomatous disease 4 (5.7 %)
 Ruptured chordae 5 (7.1 %)
 Degenerative disease 28 (40 %)
 Vegetations 10 (14 %)
 MAC 38 (54 %)
 Ischemic MR (posterior restriction) 3 (4.3 %)
Concomitant procedures  
 Any 58 (83 %)
 CABG 6 (8.6 %)
 AVR, TVR, ASD repair, and/or myectomy 33 (47 %)
 CABG + AVR, TVR, ASD repair, and/or myectomy 11 (16 %)
 AVR 24 (34 %)
 Triple valve procedures 6 (8.6 %)
 Antiarrhythmic procedure (Cox maze procedure, PVI, and/or LAAL) 7 (10 %)
  1. mm millimeters, MR mitral regurgitation, MS mitral stenosis, MAC mitral annular calcification, CABG coronary artery bypass grafting, AVR aortic valve replacement, TVR tricuspid valve repair, ASD atrial septal defect, PVI pulmonary vein isolation, LAAL left atrial appendage ligation
  2. aContinuous variables expressed as mean ± standard error of the mean (SE); categorical variables, as n (percentage)
  3. bData available for only 68 patients